Improving ciprofloxacin antimicrobial activity through lipid nanoencapsulation or non-thermal plasma on Pseudomonas aeruginosa biofilms

Muraca, Giuliana; Soler-Arango, Juliana; Castro, Guillermo R.; Islan, Germán Abel; Brelles-Mariño, Graciela

doi:10.1016/j.jddst.2021.102644

Cited by 8 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of ciprofloxacin against P. aeruginosa PAO1 planktonic cells and biofilm can be boosted with NTP pre-treatment (Muraca et al 2021 ). The ciprofloxacin MIC of biofilm (200 mg/L) was reduced by one-half upon NTP pre-treatment (50–100 mg/L).…”

Section: Combination Of Ntp Pre-treatment and Atbs Actionmentioning

confidence: 99%

Overcoming antibiotic resistance: non-thermal plasma and antibiotics combination inhibits important pathogens

Vaňková,

Julák,

Machková

et al. 2024

Pathogens and Disease

View full text Add to dashboard Cite

Antibiotic resistance (ATBR) is increasing every year as the overuse of antibiotics (ATB) and the lack of newly emerging antimicrobial agents lead to an efficient pathogen escape from ATB action. This trend is alarming and the World Health Organization warned in 2021 that ATBR could become the leading cause of death worldwide by 2050. The development of novel ATB is not fast enough considering the situation, and alternative strategies are therefore urgently requested. One such alternative may be the use of non-thermal plasma (NTP), a well-established antimicrobial agent actively used in a growing number of medical fields. Despite its efficiency, NTP alone is not always sufficient to completely eliminate pathogens. However, NTP combined with ATB is more potent and evidence has been emerging over the last few years proving this a robust and highly effective strategy to fight resistant pathogens. This minireview summarizes experimental research addressing the potential of NTP-ATB combination, particularly for inhibiting planktonic and biofilm growth and treating infections in mouse models caused by methicillin-resistant Staphylococcus aureus or Pseudomonas aeruginosa. The published studies highlight this combination as a promising solution to emerging ATBR, and further research is therefore highly desirable.

show abstract

Section: Combination Of Ntp Pre-treatment and Atbs Actionmentioning

confidence: 99%

Overcoming antibiotic resistance: non-thermal plasma and antibiotics combination inhibits important pathogens

Vaňková,

Julák,

Machková

et al. 2024

Pathogens and Disease

View full text Add to dashboard Cite

show abstract

“…Drug molecules self-arrange in the spaces between fatty acid chains and in the amorphous areas of the liquid lipid, forming drug clusters [22]. We have recently demonstrated the flexibility and reliability of an NLC platform, by reporting on the suitability of multiple NLC-based formulations for the delivery of different types of drugs [25][26][27][28][29][30][31][32][33].…”

Section: Introductionmentioning

confidence: 99%

Nanostructured Lipid Carriers Loaded with Dexamethasone Prevent Inflammatory Responses in Primary Non-Parenchymal Liver Cells

et al. 2022

View full text Add to dashboard Cite

Liver inflammation represents a major clinical problem in a wide range of pathologies. Among the strategies to prevent liver failure, dexamethasone (DXM) has been widely used to suppress inflammatory responses. The use of nanocarriers for encapsulation and sustained release of glucocorticoids to liver cells could provide a solution to prevent severe side effects associated with systemic delivery as the conventional treatment regime. Here we describe a nanostructured lipid carrier developed to efficiently encapsulate and release DXM. This nano-formulation proved to be stable over time, did not interact in vitro with plasma opsonins, and was well tolerated by primary non-parenchymal liver cells (NPCs). Released DXM preserved its pharmacological activity, as evidenced by inducing robust anti-inflammatory responses in NPCs. Taken together, nanostructured lipid carriers may constitute a reliable platform for the delivery of DXM to treat pathologies associated with chronic liver inflammation.

show abstract

Assessing the antimicrobial efficacy of nonthermal plasma treatment on filamentous fungi spores and biofilms

Rabochová,

Kulišová,

Lorinčík

et al. 2024

Food Control

View full text Add to dashboard Cite

Improving ciprofloxacin antimicrobial activity through lipid nanoencapsulation or non-thermal plasma on Pseudomonas aeruginosa biofilms

Cited by 8 publications

References 58 publications

Overcoming antibiotic resistance: non-thermal plasma and antibiotics combination inhibits important pathogens

Overcoming antibiotic resistance: non-thermal plasma and antibiotics combination inhibits important pathogens

Nanostructured Lipid Carriers Loaded with Dexamethasone Prevent Inflammatory Responses in Primary Non-Parenchymal Liver Cells

Assessing the antimicrobial efficacy of nonthermal plasma treatment on filamentous fungi spores and biofilms

Contact Info

Product

Resources

About